CA2405031A1 - Guaifenesin sustained release formulation and tablets - Google Patents

Guaifenesin sustained release formulation and tablets Download PDF

Info

Publication number
CA2405031A1
CA2405031A1 CA002405031A CA2405031A CA2405031A1 CA 2405031 A1 CA2405031 A1 CA 2405031A1 CA 002405031 A CA002405031 A CA 002405031A CA 2405031 A CA2405031 A CA 2405031A CA 2405031 A1 CA2405031 A1 CA 2405031A1
Authority
CA
Canada
Prior art keywords
tablet
formulation
guaifenesin
sustained release
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002405031A
Other languages
French (fr)
Other versions
CA2405031C (en
Inventor
Ralph W. Blume
Robert D. Davis
Donald J. Keyser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RB Health US LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24233984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2405031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2405031A1 publication Critical patent/CA2405031A1/en
Application granted granted Critical
Publication of CA2405031C publication Critical patent/CA2405031C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Abstract

The invention relates to a novel pharmaceutical sustained release formulatio n of guaifenesin. The formulation may comprise a hydrophilic polymer, preferab ly a hydroxypropyl methylcellulose, and a water-insoluble polymer, preferably a n acrylic resin, in a ratio range of about one-to-one (1:1) to about six-to-on e (6:1), more preferably a range of about three-to-two (3:2) to about four-to- one (4:1), and most preferably about two-to-one (2:1), by weight. This formulation capable of providing therapeutically effective bioavailability o f guaifenesin for at least twelve hours after dosing in a human subject. The invention also relates to a modified release guaifenesin tablet which has tw o portion: the first portion comprises an immediate release formulation of guaifenesin and the second portion comprises a sustained release formulation of guaifenesin as described above. This two portion, or bi-layer, tablet has a maximum serum concentration equivalent to that of an immediate release guaifenesin tablet, and is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject.

Claims (32)

1. A sustained release pharmaceutical formulation that is capable of therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing, the formulation comprising:
(a) guaifenesin;
(b) a hydrophilic polymer; and (c) a water-insoluble polymer;
wherein the hydrophilic polymer and the water-insoluble polymer are in a weight ratio range of about 1:1 to about 6:1.
2. The formulation of claim 1 wherein the hydrophilic polymer and the water-insoluble polymer are in a weight ratio range of about 3:2 to about 4:1.
3. The formulation of claim 1 wherein the hydrophilic polymer and the water-insoluble polymer are in a weight ratio range of about 2:1.
4. The formulation of claim 1 wherein the hydrophilic polymer is selected from the group consisting of acacia, gum tragacanth, locust bean gum, guar gum, karaya gum, modified cellulosic, methylcellulose, hydroxomethylcellulose, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxyethylcellulose, carboxymethylcellulose, agar, pectin, carrageen, alginate, carboxypolymethylene, gelatin, casein, zero, bentonite, magnesium aluminum silicate, polysaccharide, modified starch derivatives, and a combination thereof.
5. The formulation of claim 4 wherein the water-insoluble polymer is selected from the group consisting of polyacrylic acids, acrylic resins, acrylic latex dispersions, cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate and a combination thereof.
6. The formulation of claim 1 wherein the hydrophilic polymer is hydroxypropyl methylcellulose and the water-insoluble polymer is an acrylic resin.
7. The formulation of claim 1 further comprising a pharmaceutical additive.
8. The formulation of claim 7 wherein the pharmaceutical additive is selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, powdered stearic acid, hydrogenated vegetable oils, talc, polyethylene glycol, mineral oil, EMERALD GREEN LADE, an FD&C color, sucrose, lactose, gelatin, starch paste, acacia, tragacanth, povidone, polyethylene glycol, Pullulan, corn syrup, colloidal silicon dioxide, talc, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, triethanolamine, polyoxyethylene sorbitan, poloxalkol, quarternary ammonium salts, mannitol, glucose, fructose, xylose, galactose, maltose, xylitol, sorbitol, potassium chloride, potassium sulfate, potassium phosphate, sodium chloride, sodium sulfate, sodium phosphate, magnesium chloride, magnesium sulfate, magnesium phosphate, microcrystalline cellulose, sodium starch glycolate, and a combination thereof.
9. The formulation of claim 7 wherein the pharmaceutical additive is a combination of magnesium stearate and EMERALD GREEN LAKE.
10. The formulation of claim 7 wherein the pharmaceutical additive is a combination of magnesium stearate and FD&C BLUE #1.
11. The formulation of claim 7 wherein about 95.5% of the formulation by weight is the guaifenesin, about 2.4% of the formulation by weight is the hydrophilic polymer, about 1.2% of the formulation by weight is the water-insoluble polymer, and about 1% of the formulation by weight is the pharmaceutical additive.
12. A modified release bi-layer tablet comprising:
(a) an immediate release portion; and (b) a sustained release portion;
wherein the immediate release portion comprises guaifenesin which becomes fully bioavailable in a subject's stomach, and the sustained release portion comprises the sustained release formulation of claim 1.
13. The modified release bi-layer tablet of claim 12 wherein the Cmax, AUCinf and AUC0-12 are approximately directly proportional for each dosage strength.
14. A modified release bi-layer tablet comprising:
(a) an immediate release portion; and (b) a sustained release portion;

wherein the immediate release portion comprises guaifenesin which becomes fully bioavailable in a subject's stomach, and the sustained release portion comprises the sustained release formulation of claim 11.
15. A modified release capsule comprising:
(a) an immediate release portion; and (b) a sustained release portion;
wherein the immediate release portion comprises guaifenesin which becomes fully bioavailable in a subject's stomach, and the sustained release portion comprises the sustained release formulation of claim 11.
16. A modified release tablet having two portions, wherein a first portion is an immediate release formulation comprising:
(a) a first quantity of guaifenesin; and (b) a first pharmaceutical additive;
and a second portion is a sustained release formulation comprising:
(a) a second quantity of guaifenesin;
(b) a hydrophilic polymer;
(c) a water-insoluble polymer; and (d) a second pharmaceutical additive;
wherein the hydrophilic polymer and the water-insoluble polymer are in a weight ratio range of about 1:1 to about 6:1.
17. The tablet of claim 16 wherein the hydrophilic polymer and the water-insoluble polymer are in a weight ratio range of about 3:2 to about 4:1.
18. The tablet of claim 16 wherein the hydrophilic polymer and the water-insoluble polymer are in a weight ratio range of about 2:1.
19. The tablet of claim 16 wherein the first pharmaceutical additive and the second pharmaceutical additive are selected from the group consisting of magnesium stearate, calcium stearate, zinc stearate, powdered stearic acid, hydrogenated vegetable oils, talc, polyethylene glycol, mineral oil, Emerald Green Lake, an FD&C color, sucrose, lactose, gelatin, starch paste, acacia, tragacanth, povidone, polyethylene glycol, Pullulan, corn syrup, colloidal silicon dioxide, talc, sodium lauryl sulfate, dioctyl sodium sulfosuccinate, triethanolamine, polyoxyethylene sorbitan, poloxalkol, quarternary ammonium salts, mannitol, glucose, fructose, xylose, galactose, maltose, xylitol, sorbitol, potassium chloride, potassium sulfate, potassium phosphate, sodium chloride, sodium sulfate, sodium phosphate, magnesium chloride, magnesium sulfate, magnesium phosphate, microcrystalline cellulose, sodium starch glycolate, and combinations thereof.
20. The tablet of claim 16 wherein the hydrophilic polymer is hydroxypropyl methylcellulose.
21. The tablet of claim 20 wherein the water insoluble polymer is an acrylic resin.
22. The tablet of claim 21 wherein a ratio of the second quantity of guaifenesin to the first quantity of guaifenesin is 5:1.
23. The tablet of claim 20 wherein a ratio of the second quantity of guaifenesin to the first quantity of guaifenesin is about 5:1.
24. The tablet of claim 23 wherein the first pharmaceutical additive is a combination of microcrystalline cellulose, sodium starch glycolate, and magnesium stearate, and the second pharmaceutical additive is a combination of magnesium stearate and Emerald Green Lake.
25. A modified release tablet comprising guaifenesin wherein the tablet demonstrates a Cmax equivalent to an immediate release guaifenesin tablet and wherein the tablet is capable of providing therapeutically effective bioavailability of guaifenesin for at least twelve hours after dosing in a human subject according to serum analysis.
26. The tablet of claim 25 wherein the guaifenesin is in a quantity of 1200 mg.
27. The tablet of claim 26 wherein the Cmax of said tablet is from about 1600 to 2500 g/mL and said tablet has an AUCinf of from about 5600 to 8750 hr* g/mL.
28. The tablet of claim 27 wherein the Cmax of said tablet is at least 1900 µg/mL and said tablet has an AUCinf of at least 7000 hr*µg/mL.
29. The tablet of claim 25 wherein the guaifenesin is in a quantity of 600 mg.
30. The tablet of claim 29 wherein the Cmax of said tablet is from about 800 to 1250 µg/mL and said tablet has an AUCinf of from about 2800 to 4375 hr*µg/mL.
31. The tablet of claim 30 wherein the Cmax of said tablet is at least 1000 µg/mL and said tablet has an AUCinf of at least 3500 hr*µg/mL.
32. The tablet of claim 25 wherein said tablet has a half life, according to serum analysis, of at least 3 hours.
CA2405031A 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets Expired - Lifetime CA2405031C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/559,542 US6372252B1 (en) 2000-04-28 2000-04-28 Guaifenesin sustained release formulation and tablets
US09/559,542 2000-04-28
PCT/US2001/013379 WO2001082895A2 (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets

Publications (2)

Publication Number Publication Date
CA2405031A1 true CA2405031A1 (en) 2001-11-08
CA2405031C CA2405031C (en) 2011-12-06

Family

ID=24233984

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2405031A Expired - Lifetime CA2405031C (en) 2000-04-28 2001-04-26 Guaifenesin sustained release formulation and tablets

Country Status (17)

Country Link
US (1) US6372252B1 (en)
EP (2) EP1276467B1 (en)
JP (1) JP2003531849A (en)
AT (1) ATE391494T1 (en)
AU (2) AU2001255680B2 (en)
CA (1) CA2405031C (en)
CY (1) CY1108166T1 (en)
DE (1) DE60133538T2 (en)
DK (1) DK1276467T3 (en)
ES (1) ES2301537T3 (en)
HK (1) HK1052651A1 (en)
IL (3) IL152012A0 (en)
MX (1) MXPA02010556A (en)
NZ (1) NZ521959A (en)
PT (1) PT1276467E (en)
TW (2) TWI326602B (en)
WO (1) WO2001082895A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596298B2 (en) * 1998-09-25 2003-07-22 Warner-Lambert Company Fast dissolving orally comsumable films
CA2328628A1 (en) * 1999-12-21 2001-06-21 Cecile J. Schoenheider Moldable compositions
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US20030012820A1 (en) * 2001-06-12 2003-01-16 Upadhyay Ajay Hasmukhlal Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom
JP2005509605A (en) * 2001-09-28 2005-04-14 マクニール−ピーピーシー・インコーポレイテッド A dosage form comprising an edible composition and an edible skin
WO2003086267A2 (en) * 2002-04-10 2003-10-23 Miller Fred H Multi-phase, multi-compartment capsular system
MXPA04010225A (en) * 2002-04-15 2005-07-05 Adams Lab Inc Sustained release of guaifenesin combination drugs.
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US20050152967A1 (en) * 2003-03-28 2005-07-14 Pfab, Lp Dynamic variable release
ATE454138T1 (en) * 2003-08-08 2010-01-15 Biovail Lab Int Srl MODIFIED RELEASE TABLET OF BUPROPION HYDROCHLORIDE
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20050096311A1 (en) * 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US20050232986A1 (en) * 2003-12-17 2005-10-20 David Brown Dosage form containing promethazine and another drug
US20070003622A1 (en) * 2004-12-16 2007-01-04 Sovereign Pharmaceuticals, Ltd. Diphenhydramine containing dosage form
US9592197B2 (en) * 2004-12-16 2017-03-14 Sovereign Pharmaceuticals, Llc Dosage form containing diphenhydramine and another drug
RS51527B2 (en) * 2004-08-13 2018-02-28 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006070406A1 (en) * 2004-12-29 2006-07-06 J.B. Chemicals & Pharmaceuticals Ltd Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20060257473A1 (en) * 2005-05-11 2006-11-16 Porranee Puranajoti Extended release tablet
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
US20080064694A1 (en) * 2006-09-11 2008-03-13 Auriga Laboratories, Inc. Multi-Phase Release Methscopolamine Compositions
WO2008033155A1 (en) * 2006-09-15 2008-03-20 Auriga Laboratories, Inc. Kits for prevention and treatment of rhinitis
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
KR101569604B1 (en) 2007-12-28 2015-11-16 임팩스 라보라토리즈, 인코포레이티드 Controlled release formulations of levodopa and uses thereof
US20090202633A1 (en) * 2008-01-03 2009-08-13 Siva Ramakrishna Velaga Extended release formulations of guaifenesin
TWI541246B (en) 2008-12-08 2016-07-11 歐陸斯迪公司 Dihydroetorphine
US20110065744A1 (en) * 2009-09-12 2011-03-17 Reckitt Benckiser Inc. Method Of Inhibiting Mucin Secretion
US9339478B2 (en) 2011-02-04 2016-05-17 Reckitt Benckiser Llc Pharmaceutical formulation
JP2011140510A (en) * 2011-03-17 2011-07-21 Biovail Lab Inc Modified-release tablet of bupropion hydrochloride
US20130172381A1 (en) 2012-01-03 2013-07-04 Chandrashekar Giliyar Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
US10098845B2 (en) 2013-10-07 2018-10-16 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
JP6184903B2 (en) * 2014-06-04 2017-08-23 ヴァレアント インターナショナル バミューダＶａｌｅａｎｔ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｂｅｒｍｕｄａ Bupropion hydrochloride modified release tablets
TWI535784B (en) 2014-08-26 2016-06-01 財團法人工業技術研究院 Shear thickening formulation and composite material employing the same
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation
CN105832671A (en) * 2016-04-13 2016-08-10 中国药科大学 Dry suspension for controlled-release of medicine and preparation method of dry suspension
WO2020180691A1 (en) * 2019-03-01 2020-09-10 Avadel Legacy Pharmaceuticals, Llc Liquid guaifenesin compositions with stable extended release profiles

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
DE1467781A1 (en) 1963-07-15 1968-12-05 Boehringer Sohn Ingelheim Process for the production of coated tablets with extended release of active ingredients
US3362880A (en) 1963-09-20 1968-01-09 Dow Chemical Co Compressed drug tablets of ethyl cellulose, glyceryl monostearate, karaya gum, tragacanth, talc, and magnesium stearate
US3555151A (en) 1966-12-21 1971-01-12 Richardson Merrell Inc Long acting solid antacid
US3981984A (en) 1968-04-01 1976-09-21 Colorcon Incorporated Color film coating of tablets and the like
US3870790A (en) 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4167558A (en) 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4140755A (en) 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4122157A (en) 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
US4226849A (en) 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4357469A (en) 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4543370A (en) 1979-11-29 1985-09-24 Colorcon, Inc. Dry edible film coating composition, method and coating form
US4259314A (en) 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
US4369172A (en) 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4540566A (en) 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
US4695464A (en) 1984-10-09 1987-09-22 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4851392A (en) 1985-02-05 1989-07-25 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
JPS61286330A (en) * 1985-06-11 1986-12-16 Teijin Ltd Slow-releasing medicinal preparation for oral administration
EP0227814A1 (en) 1985-07-02 1987-07-08 The Upjohn Company Therapeutic formulations with bimodal release characteristics
US4704285A (en) 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
US4699779A (en) 1986-02-18 1987-10-13 Victor Palinczar Waterproof sunscreen compositions
IT1191674B (en) 1986-03-07 1988-03-23 Eurand Spa FORMULATIONS FOR THE PREPARATION OF PROLONGED-RELEASE DRUGS SUITABLE FOR ORAL ADMINISTRATION
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4798725A (en) 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
CH668553A5 (en) 1987-02-02 1989-01-13 Mepha Ag MEDICINAL PRODUCTS WITH DELAYED RELEASE OF THE ACTIVE SUBSTANCE.
NZ223619A (en) * 1987-02-27 1990-10-26 Lilly Co Eli Sustained release tablet containing cefaclor, a hydrophilic polymer and an acrylic polymer
US4968508A (en) 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4786503A (en) 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5200193A (en) 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4994276A (en) 1988-09-19 1991-02-19 Edward Mendell Co., Inc. Directly compressible sustained release excipient
JPH01153626A (en) * 1987-12-10 1989-06-15 Nippon Soda Co Ltd Sustained release spherical particle preparation
US4983398A (en) 1987-12-21 1991-01-08 Forest Laboratories, Inc. Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates
US5032406A (en) 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
KR0178391B1 (en) 1989-07-18 1999-05-15 토마스 디. 몰리터노 Polymer base blend compositions containing destructured starch
FR2666340A1 (en) 1990-08-30 1992-03-06 Warner Lambert Co NOVEL COMPOSITIONS COMPRISING A HYDROPHILIC POLYMER AND A HYDROPHILIC MATERIAL DIFFERENT FROM THE FIRST.
US5098715A (en) 1990-12-20 1992-03-24 Burroughs Wellcome Co. Flavored film-coated tablet
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
US5164398A (en) 1991-04-01 1992-11-17 Merck & Co., Inc. Ibuprofen-antitussive combinations
US5208037A (en) 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
IT1250421B (en) 1991-05-30 1995-04-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES.
US5292534A (en) 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
US5656296A (en) * 1992-04-29 1997-08-12 Warner-Lambert Company Dual control sustained release drug delivery systems and methods for preparing same
ES2194863T3 (en) * 1992-11-30 2003-12-01 Kv Pharm Co PHARMACEUTICAL MATERIALS WITH MASK OF FLAVOR.
JPH06316517A (en) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd Sustained-release preparation
IT1264517B1 (en) 1993-05-31 1996-09-24 Ekita Investments Nv PHARMACEUTICAL TABLET SUITABLE FOR THE RELEASE IN SUBSEQUENT TIMES OF THE ACTIVE PRINCIPLES CARRIED THEREIN
US5662933A (en) 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5395626A (en) 1994-03-23 1995-03-07 Ortho Pharmaceutical Corporation Multilayered controlled release pharmaceutical dosage form
IT1282650B1 (en) 1996-02-19 1998-03-31 Jagotec Ag PHARMACEUTICAL TABLET, CHARACTERIZED BY A HIGH INCREASE IN VOLUME IN CONTACT WITH BIOLOGICAL LIQUIDS
JPH1017497A (en) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd Sustained release pharmaceutical preparation and its production
US5807580A (en) 1996-10-30 1998-09-15 Mcneil-Ppc, Inc. Film coated tablet compositions having enhanced disintegration characteristics
WO1998022097A2 (en) * 1996-11-20 1998-05-28 Bio Advances, Llc Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
FR2772615B1 (en) * 1997-12-23 2002-06-14 Lipha MULTILAYER TABLET FOR INSTANT RELEASE THEN PROLONGED ACTIVE SUBSTANCES
US5968554A (en) 1998-07-07 1999-10-19 Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. Sustained release pharmaceutical preparation

Also Published As

Publication number Publication date
TW200727919A (en) 2007-08-01
EP1276467A2 (en) 2003-01-22
DK1276467T3 (en) 2008-08-04
AU2001255680B2 (en) 2006-02-16
EP1276467B1 (en) 2008-04-09
ATE391494T1 (en) 2008-04-15
AU5568001A (en) 2001-11-12
ES2301537T3 (en) 2008-07-01
CA2405031C (en) 2011-12-06
IL190742A0 (en) 2008-11-03
TWI326602B (en) 2010-07-01
JP2003531849A (en) 2003-10-28
HK1052651A1 (en) 2003-09-26
DE60133538D1 (en) 2008-05-21
EP1913937A1 (en) 2008-04-23
IL152012A0 (en) 2003-04-10
US6372252B1 (en) 2002-04-16
PT1276467E (en) 2008-05-15
NZ521959A (en) 2004-10-29
DE60133538T2 (en) 2009-07-09
WO2001082895A2 (en) 2001-11-08
WO2001082895A3 (en) 2002-05-23
MXPA02010556A (en) 2003-10-14
IL152012A (en) 2010-04-15
CY1108166T1 (en) 2014-02-12
TWI314866B (en) 2009-09-21

Similar Documents

Publication Publication Date Title
CA2405031A1 (en) Guaifenesin sustained release formulation and tablets
AU719170B2 (en) Pharmaceutical compressed tablet characterized by a high increase in volume by contact with biological fluids
AU740421B2 (en) Bioadhesive tablets
US8303986B2 (en) Hydrophilic/lipophilic polymeric matrix dosage formulation
EP1058538B9 (en) Fast disintegrating tablets
US20090104263A1 (en) 5-HT4 partial agonist pharmaceutical compositions
WO2005105036A1 (en) Controlled release mucoadhesive matrix formulation containing tolterodine and a process for its preparation
WO2002092078A1 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
JP4894958B2 (en) Water-soluble drug sustained release technology
JP2004502723A (en) Oral pharmaceutical composition with sustained release and delayed absorption
CA2182004C (en) Film coated tablet of paracetamol and domperidone
US20020119192A1 (en) Controlled release formulations for oral administration
CA2411882A1 (en) Solid valsartan pharmaceutical compositions
US20220079937A1 (en) Pharmaceutical formulation
US8617596B2 (en) Sustained-release tablet production process
KR101277021B1 (en) Oral controlled release double-layered rebamipide-contained formulation using gastro-retentive drug delivery system and process for the preparation thereof
US20100285125A1 (en) Delivery system for poorly soluble drugs
EP1512394A1 (en) Universal controlled-release composition comprising chitosan
MXPA06010805A (en) Clarithromycin extended release formulation.
JP3282832B2 (en) Sustained tablets
US20080063707A1 (en) Controlled release tablet formulations for the prevention of arrhythmias
CA2394588A1 (en) Controlled release kcl tablet formulations

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210426

MKEX Expiry

Effective date: 20210426